TY - JOUR
T1 - Women's cannabis use before, during, and after pregnancy in New Hampshire
AU - Skelton, Kara R.
AU - Hecht, Amelie A.
AU - Benjamin-Neelon, Sara E.
N1 - Funding Information:
We thank all PRAMS study participants and members of the PRAMS Working Group: Alabama—Tammie Yelldell, MPH; Alaska—Kathy Perham-Hester, MS, MPH; Arizona – Enid Quintana-Torres, MPH; Arkansas— Letitia de Graft-Johnson, DrPH, MHSA; Colorado—Ashley Juhl, MSPH; Connecticut—Jennifer Morin, MPH; Delaware—George Yocher, MS; Florida—Tara Hylton, MPH; Georgia—Florence A. Kanu, PhD, MPH; Hawaii—Matt Shim, PhD, MPH; Illinois— Julie Doetsch, MA; Indiana – Brittany Reynolds, MPH; Iowa—Jennifer Pham; Kentucky—Tracey D. Jewell, MPH; Louisiana—Rosaria Trichilo, MPH; Maine—Tom Patenaude, MPH; Maryland—Laurie Kettinger, MS; Massachusetts—Hafsatou Diop, MD, MPH; Michigan—Peterson Haak; Minnesota—Mira Grice Sheff, PhD, MS; Mississippi—Brenda Hughes, MPPA; Missouri—Venkata Garikapaty, PhD; Montana—Emily Healy, MS; Nebraska—Jessica Seberger; New Hampshire—David J. Laflamme, PhD, MPH; New Jersey—Sharon Smith Cooley, MPH; New Mexico—Sarah Schrock, MPH; New York State—Anne Radigan; New York City— Lauren Birnie, MPH; North Carolina—Kathleen Jones-Vessey, MS; North Dakota— Grace Njau, MPH; Oklahoma—Ayesha Lampkins, MPH, CHES; Oregon— Cate Wilcox, MPH; Pennsylvania—Sara Thuma, MPH; Puerto Rico – Wanda Hernandez, MPH; Rhode Island—Karine Tolentino Monteiro, MPH; South Carolina— Harley T. Davis, PhD, MPSH; South Dakota – Maggie Minett; Texas—Tanya Guthrie, PhD; Tennessee—Ransom Wyse, MPH, CPH; Utah—Nicole Stone, MPH; Vermont—Peggy Brozicevic; Virginia—Kenesha Smith, PhD, MSPH; Washington—Linda Lohdefinck; West Virginia—Melissa Baker, MA; Wisconsin—Fiona Weeks, MSPH; Wyoming—Lorie Chesnut, PhD. We also thank the following persons with funding or employment by the Centers for Disease Control and Prevention: Gary Stuart; Brian Morrow, MA; Leslie Harrison, MPH; and members of the PRAMS Team, Women's Health and Fertility Branch, Division of Reproductive Health.
Publisher Copyright:
© 2020 The Authors
PY - 2020/12
Y1 - 2020/12
N2 - Cannabis use in the United States has been steadily increasing. Much more is known about cannabis users in states where recreational cannabis is legal, compared to states yet to legalize. Further, there is little information known about reasons for cannabis use during critical maternal and child health periods. To address this gap, we examined cannabis use among New Hampshire women during the preconception, prenatal, and postpartum periods, and explored reasons for use. We analyzed data from the 2016–2017 Pregnancy Risk Assessment Monitoring System (PRAMS) in the Spring of 2020. For women delivering a live-born infant, PRAMS collects behavior and experience data before, during, and after pregnancy. Using data from New Hampshire, we estimated the weighted prevalence of self-reported cannabis use during the preconception, prenatal, and postpartum periods, and reasons for use during each period. Of the 1147 women included in the analysis, 16.8% (unweighted n = 186) reported preconception cannabis use, 5.5% (unweighted n = 68) reported prenatal cannabis use, and 6.6% (unweighted n = 73) reported postpartum cannabis use. About one-fifth (20.3%) of women who reported cannabis use reported use during all three periods. The top reason for cannabis use during preconception and postpartum was for stress or anxiety relief (64.88% and 73.06, respectively), and during the prenatal period was for its’ antiemetic properties (84.1%). Our findings support that women's healthcare providers should screen patients for cannabis use, addressing underlying reasons (e.g., mental health issues, nausea/vomiting) for use as part of the screening process.
AB - Cannabis use in the United States has been steadily increasing. Much more is known about cannabis users in states where recreational cannabis is legal, compared to states yet to legalize. Further, there is little information known about reasons for cannabis use during critical maternal and child health periods. To address this gap, we examined cannabis use among New Hampshire women during the preconception, prenatal, and postpartum periods, and explored reasons for use. We analyzed data from the 2016–2017 Pregnancy Risk Assessment Monitoring System (PRAMS) in the Spring of 2020. For women delivering a live-born infant, PRAMS collects behavior and experience data before, during, and after pregnancy. Using data from New Hampshire, we estimated the weighted prevalence of self-reported cannabis use during the preconception, prenatal, and postpartum periods, and reasons for use during each period. Of the 1147 women included in the analysis, 16.8% (unweighted n = 186) reported preconception cannabis use, 5.5% (unweighted n = 68) reported prenatal cannabis use, and 6.6% (unweighted n = 73) reported postpartum cannabis use. About one-fifth (20.3%) of women who reported cannabis use reported use during all three periods. The top reason for cannabis use during preconception and postpartum was for stress or anxiety relief (64.88% and 73.06, respectively), and during the prenatal period was for its’ antiemetic properties (84.1%). Our findings support that women's healthcare providers should screen patients for cannabis use, addressing underlying reasons (e.g., mental health issues, nausea/vomiting) for use as part of the screening process.
KW - Marijuana
KW - Maternal health
KW - Substance use
UR - http://www.scopus.com/inward/record.url?scp=85097394089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097394089&partnerID=8YFLogxK
U2 - 10.1016/j.pmedr.2020.101262
DO - 10.1016/j.pmedr.2020.101262
M3 - Article
C2 - 33318887
AN - SCOPUS:85097394089
SN - 2211-3355
VL - 20
JO - Preventive Medicine Reports
JF - Preventive Medicine Reports
M1 - 101262
ER -